INTRODUCTION

General anesthesia and sleep have long been discussed in the neurobiological context owing to their commonalities such as unconsciousness, immobility, non-responsiveness to external stimuli, and lack of memory upon returning to consciousness. In 1855, it was hypothesized that a common mechanism might be involved in general anesthesia and normal deep sleep [1]. However, since the exact mechanisms of anesthesia and sleep are yet to be completely understood, the relationship between the two phenomena remains uncertain. This review discusses the current understanding of neurobiological mechanisms underlying sleep and anesthesia and explores potential clinical implications. Based on the similarities and differences between these seemingly similar states, we sought to gain a better insight into anesthesiology and sleep medicine.

DEFINITION OF GENERAL ANESTHESIA AND SLEEP

The American Society of Anesthesiologists defined general anesthesia as “drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation” [2]. This condition is also accompanied by amnesia, akinesia, and the stability of life-sustaining physiological systems [3]. Sleep is characterized by immobility and a reduced level of responsiveness to the environment, unlike the awake state, and differs from hibernation or anesthesia in that it is quickly reversible [4]. Sleep is often regarded as a passive state; however, it is a dynamic process that is regulated by complex mechanisms rather than a state of inactivity. Sleep states are categorized into the following two distinct phases: rapid eye movement (REM) and non-rapid eye movement (NREM) sleep. REM sleep is accompanied by bursts of rapid eye movements, irregular breathing and
heart rate, dreams, and muscular atonia, whereas NREM sleep is characterized by slow eye movement, decreased muscle tone, body temperature, and heart rate [5].

ELECTROENCEPHALOGRAPHIC FINDINGS IN GENERAL ANESTHESIA AND SLEEP

Electroencephalograms (EEG) reveal distinct patterns during general anesthesia. As the depth of anesthesia increases, the EEG pattern changes from paradoxical excitation, phases 1 and 2, followed by burst suppression and isoelectric traces [3].

During the induction period, EEG shows an increase in beta activity (13–25 Hz), implying a paradoxically excited brain status. Under lighter phases anesthesia (phase 1), EEG beta activity decreases while alpha (8–12 Hz) and delta (0.5–4 Hz) activities increase. An intermediate state (phase 2) is characterized by increased alpha and delta activity in the anterior brain, called anteriorization. The EEG of phase 2 anesthesia is similar to that of stage 3 NREM sleep. Under more profound anesthetic state (phase 3), a critical feature on EEG is intermittent high-power range oscillations (bursts) in alternation with isoelectricity (suppression), which is known as burst suppression [6–9]. This distinct feature is mainly observed when the brain is inactivated, such as during hypothermia [10–12], deep general anesthesia [3,13], and coma [14]. Surgical procedures are usually conducted in phases 2 and 3.

EEG during sleep also shows distinct stages. In NREM stage 1, the EEG frequency decreases, and strong alpha and theta activities are observed. In NREM stages 2 and 3, the amplitude of EEG increases, and the frequency reduces further, which are characterized by both sleep spindles (7–14 Hz) and K-complexes. In NREM stage 4, brain waves show high-amplitude and low-frequency rhythms. In particular, large-amplitude delta waves (0.5–4 Hz) are characteristic of NREM sleep stage 4, also known as slow-wave sleep. During REM sleep, EEG shows high-frequency and low-amplitude rhythms, and theta (7–9 Hz) activity is prominently observed [15]. More information can be found in the review by Brown et al. [3].

REGULATORY MECHANISMS FOR SLEEP AND WAKEFULNESS IN THE BRAIN

Arousal pathway

Activation of wake-promoting systems causes arousal in an organism and prevents it from falling asleep. During states of wakefulness, low-amplitude oscillations at 20–60 Hz were found in the cortical EEG, and an electromyogram (EMG) shows irregular muscle activities [16–18]. According to Moruzzi and Magoun [19], the waking state is maintained by an ascending flow of arousal signals emanating from the brainstem reticular formation. The ascending reticular activating system (ARAS) is generally located in the pons and midbrain. In addition to ARAS, many other wake-promoting areas were identified [20,21]. Recent advances in neuroscientific techniques have enabled the identification of intracerebral nuclei and their neurotransmitter-specific cell types which maintain or promote wakefulness. Optogenetics and chemogenetics have revolutionized the anatomical and physiological understanding of sleep and wakefulness. Optogenetics is a cutting-edge neurotechnology that uses light-sensitive proteins, such as channelrhodopsin, and illumination to control the activity of neurons in a cell-type- and region-specific manner with high temporal precision. Neurons induce or suppress action potentials when light-sensitive ion channels or pumps are stimulated optically [22]. Similarly, chemogenetics employs mutated muscarinic receptors, such as hM3Dq and hM4Di, which are responsive to the exogenous chemical clozapine-N-oxide (CNO) but not to the endogenous ligand acetylcholine. After hM3Dq or hM4Di is expressed in a specific group of cells, the specific neurons can be excited or inhibited selectively by CNO administration. Wake-promoting cell groups include noradrenergic cells in the locus ceruleus (LC) [23], 5-HT-synthesizing (serotonergic) cells in the dorsal raphe nuclei (DRN) [24], acetylcholine-synthesizing (cholinergic) cells [25–28], glutamatergic, and GABAergic cells [25,27,29] in the pedunculopontine tegmentum (PPT) and laterodorsal tegmentum (LDT), and DA-synthesizing (dopaminergic) cells in the ventral tegmental area (VTA) [30]. The parabrachial nucleus (PB) is also a strong wake-promoting area that is active during hypercarbia, pain, cold, and nausea [31]. In the forebrain, some nuclei promote wakefulness in conjunction with ARAS [16], including histaminergic cells in the tuberomammillary nuclei (TMN) [32], hypocretinergic (also known as orexergic) cells in the lateral hypothalamus (LH)
[33–36], cholinergic and parvalbumin-containing cells in the basal forebrain (BF) [37], and glutamatergic neurons in the PB [31]. Activation of these systems spontaneously or experimentally leads to a pattern of cortical activation required to maintain wakefulness. However, it remains unclear whether all these cell populations are simultaneously necessary to generate and maintain wakefulness.

Sleep-promoting pathway

First, the ventrolateral preoptic area (VLPO) was discovered as a sleep-promoting area. GABAergic and galaninergic neurons in the VLPO project to wake-promoting brain regions, such as the TMN, DRN, LC, PB, hypocretinergic neurons, and cholinergic neurons of the BF. Other areas were also found to have sleep-active neurons. The parafacial zone in the rostral medulla, which is dorsolateral to the origin of the facial nerve, contains GABAergic/glycinergic neurons. These neurons are active during NREM sleep, and their selective activation causes longer NREM sleep and higher EEG delta rhythm [38]. In the cortex, most neurons are wake-active, but neurons containing nitric oxide synthase (nNOS) in the deep layer are sleep-active [39]. These neurons fire in response to homeostatic sleep pressure and release GABA and nitric oxide, slowing down cortical rhythms. Additionally, two sets of neurons are essential for REM sleep. One is cholinergic neurons in the PPT/LDT area, which are active during REM sleep and are known as “REM-ON” cells [40]. The other is glutamatergic neurons in the sublaterodorsal nucleus, which have been discovered more recently as REM-sleep generators [41].

Flip-flop switch model

Interestingly, sleep-promoting VLPO and wake-promoting regions are connected by bidirectional inhibitory projections. This reciprocal inhibitory neural circuitry is similar to flip-flop circuitry in electronics, which enables rapid transitions between sleep and wake states and keeps the states in a stable manner. Thus, a model mechanism for sleep-wake control between VLPOs and arousal-promoting regions was proposed and named the “flip-flop switch” model [42]. Activating VLPO neurons promotes sleep by inhibiting arousal-promoting areas such as LC, TMN, and DRN neurons, whereas activating LC, TMN, and DRN neurons promote wakefulness by inactivating VLPO neurons. As a result of solid inhibition between these two sides of the switch, the system rapidly shift from one state to the other and stabilizes one state against the other. Therefore, balancing arousal-promoting and sleep-promoting circuitries is critical for determining a vigilance state.

Homeostatic sleep regulation

In general, prolonged wakefulness is followed by longer and deeper sleep. Homeostatic sleep response is characterized by a higher sleep propensity and longer sleep time after sleep deprivation (SD) [43]. Adenosine is a neurochemical substrate of sleep propensity and sleep-inducing factor that increases in proportion to prior wakefulness [44]. In contrast, slow wave activity (SWA) is considered an electrophysiological measure of sleep propensity or the tendency toward sleep and can be measured by the power of cortical delta waves (0.5–4 Hz). Homeostatic sleep response occurs during recovery sleep after SS and is characterized by increased SWA. Additionally, slow-wave energy (SWE), the time integral of SWA during NREM sleep, also represents the homeostatic sleep response.

ANESTHETIC AGENTS: GABAERGIC VS. NON-GABAERGIC

General anesthetics increase inhibitory neurotransmission and decrease excitatory neurotransmission in the central nervous system, ultimately leading to a suppressed state of the brain. However, the mechanisms of action of general anesthetics are not yet well established. In addition, the representative states of general anesthesia, including unconsciousness, amnesia, analgesia, and akinesia, are mediated by different receptors and brain regions. Most general anesthetics act on neurotransmitter-gated ion channels. It has been found that among the various ion channels, the γ-aminobutyric acid type A (GABA\(_A\)) receptor plays a significant role as a functional site for general anesthesia [45–49]. GABA is the primary inhibitory neurotransmitter in the mammalian central nervous system and its inhibition is mediated mainly through chloride-permeable chloride-gated ion channels called GABA\(_A\) receptors. Activation of GABA\(_A\) receptors triggers an inflow of chloride ions into the cell, causing cell membrane potential hyperpolarization and decreased neuronal excitability [50]. The GABA\(_A\) receptor has an active site to which GABA and other drugs, such as bicuculline, can bind as a ligand along with multiple allosteric binding sites [51]. Various anesthetics, including benzodiaz-
epines, propofol, neuroactive steroids, barbiturates, and inhaled anesthetics, can modulate receptor activity by binding to the different allosteric binding sites [52]. Non-GABAergic agents such as ketamine [53], nitrous oxide [54], and xenon [55] rarely interact with GABA_A receptors. The anesthetic effects are mediated by non-competitive antagonism of the N-methyl-D-aspartic acid (NMDA) receptor, resulting in decreased excitatory neurotransmission. Especially, ketamine interacts with the opioid, monoaminergic, cholinergic, purinergic, and adrenoreceptor systems [56, 57].

**THE ACTION OF ANESTHETICS BLOCKING THE AROUSAL PATHWAY**

**Tuberomammillary nucleus**

The TMN is a critical wake-promoting nucleus and a target for anesthesia-induced sedation [58]. In particular, after sedation induced by GABAergic anesthetics such as propofol, muscimol, and pentobarbital, the expression pattern of the c-Fos gene, a marker of neuronal activity, appears similar to that of NREM sleep. Expression of c-Fos, a marker for neuronal activation, decreased in TMN while increased in the VLPO, suggesting that GABAergic agents activate the VLPO and suppress the TMN. Furthermore, muscimol directly injected into the TMN increased the loss of righting response (LORR) time, a behavioral measure of the degree of sedation, in a dose-dependent manner, whereas GABAA receptor antagonist, gabazine reduced the LORR [58, 59]. These findings suggest that GABAergic anesthetics inhibit neuronal activity in the TMN, resulting in reduced release of histamine and loss of consciousness [60, 61].

**Hypocretinergic neurons**

Hypocretinergic neurons also mediate anesthetic effects by decreasing their wake-promoting functions. Evidence suggests that isoflurane and sevoflurane decrease c-Fos expression in hypocretinergic neurons, also known as orexinergic neurons, implying that their activity is suppressed [64]. More recently, these neurons in the perifornical area of the lateral hypothalamus have demonstrated influencing the maintenance and emergence from isoflurane and desflurane anesthesia [65]. In addition, these neurons also affect induction via projections to the paraventricular nucleus.

**DOES ANESTHESIA HAVE SLEEP-LIKE EFFECTS?**

To date, many researchers have concluded that sleep and anesthesia are distinct states, but they share several similarities [66, 67]. Although it is already known that anesthetics can induce sedation by acting on arousal neural circuits [58], no clear evidence showed that sleep-promoting nuclei cause sedation until volatile anesthetics, such as isoflurane or halothane, was examined for the activity of the sleep-promoting VLPO region by measuring the expression level of c-Fos [68]. As a result of volatile anesthetics administered during the dark period, an active period for the rodents, c-Fos-positive neurons increased in a dose-dependent manner, similar to the activation level of VLPO neurons during spontaneous sleep during the light period.

**CAN ANESTHESIA REDUCE SLEEP PROPENSITY?**

Sleep characteristics are homeostatically regulated based on the length and depth of previous sleep. Therefore, it is reasonable to question whether anesthesia can function in the same manner as sleep homeostasis. General anesthesia with a slow-wave or isoelectric EEG after sleep deprivation can result in a blunted SWA rebound, implying that anesthesia may have a similar effect to NREM sleep [69]. According to a study comparing the cumulative SWE of the group that received isoflurane for 1 h immediately after sleep deprivation for 4 h against the group that did not receive isoflurane, the slope of rebound sleep was flattened in the group treated with isoflurane [69]. This phenomenon can have two inferences. First, anesthesia may have caused an abnormal brain condition suppressing SWA and the abnormality sustained...
during recovery sleep. Another possibility is that anesthesia may have resolved the accumulated sleep pressure by an unknown mechanism. However, because both the high and low doses of anesthetic agents reduced SWA during recovery sleep and only a low dose could generate slow waves, anesthesia SWA may not be necessary for the sleep-like effect. Instead, there may be an unknown mechanism that mediates the sleep-like effects of general anesthesia. Sevoflurane may have similar but different effects on NREM and REM sleep. Six-hour sevoflurane anesthesia following 12-h sleep deprivation reduced the homeostatic response in NREM sleep but not in REM sleep [70]. Sevoflurane treatment after sleep deprivation reduced rebound sleep compared with no sevoflurane treatment, suggesting that homeostatic sleep pressure was partly resolved by sevoflurane anesthesia.

**CAN ANESTHESIA AMELIORATE SD-INDUCED COGNITIVE DYSFUNCTION?**

Sleep deprivation is commonly associated with memory impairment, one of the most prevalent symptoms. Therefore, it is unclear whether sedation with anesthetics also reduces SD-induced memory impairments. Dexmedetomidine, a selective α2-adrenergic receptor agonist, appears to counteract memory impairment induced by sleep deprivation [71]. Chronically sleep-deprived mice simultaneously treated with dexmedetomidine showed decreased memory impairment. Simultaneously, they showed lower levels of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, and increased levels of neuroprotective signaling molecules, such as brain-derived neurotrophic factor (BDNF) and tyrosine kinase B (TrkB). Dexmedetomidine reduces detrimental responses caused by sleep deprivation, potentially resembling sleep effects.

**DOES SLEEP PRESSURE POTENTIATE THE EFFECTS OF THE ANESTHETICS?**

We have reviewed that anesthesia may have sleep-like effects. In contrast, whether sleepiness or sleep deprivation can affect anesthesia is a clinically important question. Twenty-four-hour sleep-deprived rats showed a shorter time taken for loss of righting reflex and a longer time to recovery when anesthetized with propofol and isoflurane. Given that preoperative sleep disturbance is associated with an increased risk of postoperative delirium [73] and that increased sleep pressure may potentiate the efficacy of anesthetic agents [72], it is clinically relevant to determine whether dose reduction could be considered for patients with either a pre-existing medical or psychiatric condition that hinders sleep chronically, or acute preoperative sleep disruption, or both. These findings suggest that sleep propensity could contribute to the response to anesthetics and that sleep quantity and quality may contribute to individual differences in responses to anesthetics.

**CHALLENGES TO THE “SHARED CIRCUIT HYPOTHESIS”**

The “shared circuit hypothesis” proposes that the activation of sleep-promoting neurons is necessary or sufficient for attainingunarousable unconsciousness or general anes-
In anesthesia [33]. This hypothesis has persisted for a long time but has recently been challenged. Ablation of the VLPO, a major sleep-promoting area, could increase the sensitivity to isoflurane. However, VLPO-ablated rats did not lose the ability to achieve deep isoflurane anesthesia [74]. In addition, a recent study by Vanini et al. showed that selective activation of VLPO using chemogenetics did not facilitate anesthesia. Briefly, they selectively activated GABAergic neurons in the VLPO by activating the hM3Dq receptor with CNO and found no difference in the time taken for loss and recovery of consciousness by isoflurane anesthesia. These findings disprove that VLPO is not necessary or sufficient to induce general anesthesia. Nevertheless, it should be noted that there are multiple levels of anesthetic action (Fig. 1). Anesthetic agents can cause unconscious but arousable states by acting on sleep-promoting areas, such as the VLPO, LH, LC, and TMN. For a deeper level of anesthesia, such as the unconscious and non-arousable state, anesthetics should act directly on the neural substrate of consciousness [75].

CONCLUSION

Recent advances in understanding the neurobiology of sleep, wakefulness, and anesthesia have elucidated the bidirectional relationship between sleep and anesthesia. Neural circuits of sleep-wake regulation are affected by anesthetics, and, in turn, anesthesia is affected by sleep propensity. Although sleep and anesthesia do not occur simply by the same mechanism or neural circuitry, their interaction might be important and meaningful for future investigations. Systematic research on the relationship between sleep disturbance and anesthesia is warranted.

FUNDING

This work was supported by the 2022 Joint Research Project of the Institutes of Science and Technology, South Korea.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.

AUTHOR CONTRIBUTIONS

Conceptualization: Tae Kim. Data curation: Jieun Jung, Tae Kim. Funding acquisition: Tae Kim. Writing - original draft: Jieun Jung. Writing - review & editing: Tae Kim. Investigation: Jieun Jung. Resources: Jieun Jung. Supervision: Tae Kim. Validation: Tae Kim.

ORCID

Jieun Jung, https://orcid.org/0000-0002-4794-9227
Tae Kim, https://orcid.org/0000-0003-0201-5401

REFERENCES

1. Fleming A. Note on the induction of sleep and anaesthesia by compression of the carotids. Br Foreign Med Chir Rev 1855; 15: 529-30.
2. Committee on Quality Management and Departmental Administration. Continuum of depth of sedation: definition of general anesthesia and levels of sedation/analgesia. American Society of Anesthesiologists [Internet]. 1999 Oct 13 [updated 2019 Oct 23; cited 2022 Oct 24]. Available from https://www.asahq.org/standards-and-guidelines/continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedationanalgesia.
3. Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. N Engl J Med 2010; 363: 2638-50.
4. Siegel JM. Clues to the functions of mammalian sleep. Nature 2005; 437: 1264-71.
5. Kryger MH, Roth T, Goldstein CA, Dement WC. Principles and practice of sleep medicine. 7th ed. Philadelphia (PA), Elsevier. 2022, pp 13-26.
6. Swank RL, Watson CW. Effects of barbiturates and ether on spontaneous electrical activity of dog brain. J Neurophysiol 1949; 12: 137-60.
7. Clark DL, Rosner BS. Neurophysiologic effects of general anesthetics. I. The electroencephalogram and sensory evoked responses in man. Anesthesiology 1973; 38: 564-82.
8. Ching S, Purdon PL, Vijayan S, Kopell NJ, Brown EN. A neurophysiological-metabolic model for burst suppression. Proc Natl Acad Sci U S A 2012; 109: 3095-100.
9. Shanker A, Abel JH, Schamburg G, Brown EN. Etiology of burst suppression EEG patterns. Front Psychol 2021; 12: 673529.
10. Marion DW, Penrod LE, Kelsey SF, Obrist WD, Kochanek PM, Palmer AM, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997; 336: 540-6.
11. Stecker MM, Cheung AT, Pochettino A, Kent GP, Patterson T,
Weiss SJ, et al. Deep hypothermic circulatory arrest: II. Changes in electroencephalogram and evoked potentials during rewarming. Ann Thorac Surg 2001; 71: 22-8.

12. Westover MB, Ching S, Kumaraswamy VM, Akeju SO, Pierce E, Cash SS, et al. The human burst suppression electroencephalogram of deep hypothermia. Clin Neurophysiol 2015; 126: 1901-14.

13. Purdon PL, Pierce ET, Mukamel EA, Prerau MJ, Walsh JL, Wong KE, et al. Electroencephalogram signatures of loss and recovery of consciousness from propofol. Proc Natl Acad Sci U S A 2013; 110: E1142-51.

14. Young GB. The EEG in coma. J Clin Neurophysiol 2000; 17: 473-85.

15. Kales A, Rechtschaffen A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, D.C., US National Institute of Neurological Diseases and Blindness, Neurological Information Network. 1968.

16. Datta S. Cellular and chemical neuroscience of mammalian sleep. Sleep Med 2010; 11: 431-40.

17. Moruzzi G. Reticular influences on the EEG. Electroencephalogr Clin Neurophysiol 1964; 16: 2-17.

18. Moruzzi G. The sleep-waking cycle. Ergeb Physiol 1972; 64: 1-165.

19. Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electroencephalogr Clin Neurophysiol 1949; 1: 455-73.

20. Datta S. Neuronal activity in the peribrachial area: relationship to behavioral state control. Neurosci Biobehav Rev 1995; 19: 67-84.

21. Datta S, Maclean RR. Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. Neurosci Biobehav Rev 2007; 31: 775-824.

22. Deisseroth K. Optogenetics. Nat Methods 2011; 8: 26-9.

23. Carter ME, Yizhar O, Chikahisa S, Nguyen H, Adamantidis A, Nishino S, et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat Neurosci 2010; 13: 1526-33.

24. Ito H, Yanase M, Yamashita A, Kitabatake C, Hamada A, Suhara Y, et al. Analysis of sleep disorders under pain using an optogenetic tool: possible involvement of the activation of dorsal raphe nucleus-serotoninergic neurons. Mol Brain 2013; 6: 59.

25. Boucetta S, Cissé Y, Mainville L, Morales M, Jones BE. Discharge profiles across the sleep-waking cycle of identified cholinergic, GABAergic, and glutamatergic neurons in the pontomesencephalic tegmentum of the rat. J Neurosci 2014; 34: 4708-27.

26. Steriade M, Dossi RC, Paré D, Oakson G. Fast oscillations (20-40 Hz) in thalamocortical systems and their potentiation by mesopontine cholinergic nuclei in the cat. Proc Natl Acad Sci U S A 1991; 88: 4396-400.

27. Kroeger D, Ferrari LL, Petit G, Mahoney CE, Fuller PM, Arrigoni E, et al. Cholinergic, glutamatergic, and GABAergic neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice. J Neurosci 2017; 37: 1352-66.

28. Van Dort CJ, Zachs DR, Kenny JD, Zheng S, Goldblum RR, Gelwan NA, et al. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc Natl Acad Sci U S A 2015; 112: 584-9.

29. Cox J, Pinto L, Dan Y. Calcium imaging of sleep-wake related neuronal activity in the dorsal pons. Nat Commun 2016; 7: 10763.

30. Eban-Rothschild A, Rothschild G, Giardino WJ, Jones JR, de Lecea L. VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. Nat Neurosci 2016; 19: 1356-66.

31. Kaur S, Pedersen NP, Yokota S, Hur EE, Fuller PM, Lazarus M, et al. Glutamatergic signaling from the parabrachial nucleus plays a critical role in hypercapnic arousal. J Neurosci 2013; 33: 7627-40.

32. Parmentier R, Zhao Y, Perier M, Akaoka H, Lintunen M, Hou Y, et al. Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: a study using a knockout mouse model. Neuropharmacology 2016; 106: 20-34.

33. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007; 450: 420-4.

34. Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci 2009; 29: 10939-49.

35. Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci U S A 2012; 109: E2635-44.

36. Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 2011; 31: 10529-39.

37. Xu M, Chung S, Zhang S, Zhong P, Ma C, Chang WC, et al. Basal forebrain circuit for sleep-wake control. Nat Neurosci 2015; 18: 1641-7.

38. Anacler C, Ferrari L, Arrigoni E, Bass CE, Saper CB, Lu J, et al. The GABAergic parafacial zone is a medullary slow wave sleep-promoting center. Nat Neurosci 2014; 17: 1217-24. Erratum in: Nat Neurosci 2014; 17: 1841.

39. Gerashchenko D, Wisor JP, Burns D, Reh RK, Shiromani PJ, Sakurai T, et al. Identification of a population of sleep-active cerebral cortex neurons. Proc Natl Acad Sci U S A 2008; 105: 10227-32.

40. Holson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science
1975; 189: 55-8.
41. Sakai K, Crochet S, Onoe H. Pontine structures and mechanisms involved in the generation of paradoxical (REM) sleep. Arch Ital Biol 2001; 139: 93-107.
42. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-63.
43. Borbély AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1: 195-204.
44. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276: 1265-8.
45. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348: 2110-24.
46. Hemnings HC Jr, Akabas MH, Goldstein PA, Trudell JR, Orser BA, Harrison NL. Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 2005; 26: 503-10.
47. Orser BA, Canning KJ, Macdonald JP. Mechanisms of general anesthesia. Curr Opin Anesthesiol 2002; 15: 427-33.
48. Franks NP. Molecular targets underlying general anesthesia. Br J Pharmacol 2006; 147(Suppl 1): S72-81.
49. Hemnings HC Jr. Sodium channels and the synaptic mechanisms of inhaled anesthetics. Br J Anaesth 2009; 103: 61-9.
50. Pearce RA. General anesthetic effects on GABAA receptors. In: Neural mechanisms of anesthesia. Edited by Antognini JJ; Carstens E, Raines DE: Totowa (NJ), Humana Press. 2003, pp 265-82.
51. Chua HC, Chebib M. GABAA receptors and the diversity in their structure and pharmacology. Adv Pharmacol 2017; 79: 1-34.
52. Johnston GA. GABAA receptor pharmacology. Pharmacol Ther 1996; 69: 173-98.
53. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-75.
54. Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4: 460-3.
55. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature 1998; 396: 324.
56. Lois F, De Kock M. Something new about ketamine for pediatric anesthesia? Curr Opin Anaesthesiol 2008; 21: 340-4.
57. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007; 21: 259-71.
58. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 2002; 5: 979-84.
59. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428-36.
60. Saper CB. Organization of cerebral cortical afferent systems in the rat. II. Hypothalamocortical projections. J Comp Neurol 1985; 237: 21-46.
61. Lin JS, Sakai K, Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 1988; 27: 111-22.
62. Du WJ, Zhang RW, Li J, Zhang BB, Peng XL, Cao S, et al. The locus coeruleus modulates intravenous general anesthesia of zebrafish via a cooperative mechanism. Cell Rep 2018; 24: 3146-55.e3.
63. Vazey EM, Aston-Jones G. Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia. Proc Natl Acad Sci U S A 2014; 111: 3859-64.
64. Kelz MB, Sun Y, Chen J, Cheng Meng Q, Moore JT, Veasey SC, et al. An essential role for orexins in emergence from general anesthesia. Proc Natl Acad Sci U S A 2008; 105: 1309-14.
65. Zhao S, Wang S, Li H, Guo J, Li J, Wang D, et al. Activation of orexinergic neurons inhibits the anesthetic effect of desflurane on consciousness state via paraventricular thalamic nucleus in rats. Anesth Analg 2021; 133: 781-93.
66. Lydic R, Baghdoyan HA. Sleep, anesthesiology, and the neurobiology of arousal state control. Anesthesiology 2005; 103: 1268-95.
67. Franks NP. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 2008; 9: 370-86.
68. Moore JT, Chen J, Han B, Meng QC, Veasey SC, Beck SG, et al. Direct activation of sleep-promoting VLPO neurons by volatile anesthetics contributes to anesthetic hypnosis. Curr Biol 2012; 22: 2008-16.
69. Nelson AB, Faraguna U, Tononi G, Cirelli C. Effects of anesthesia on the response to sleep deprivation. Sleep 2010; 33: 1659-67.
70. Pal D, Lipinski WJ, Walker AJ, Turner AM, Mashour GA. State-specific effects of sevoflurane anesthesia on sleep homeostasis: selective recovery of slow wave but not rapid eye movement sleep. Anesthesiology 2011; 114: 302-10.
71. Hwang L, Ko IG, Jin JJ, Kim SH, Kim CJ, Chang B, et al. Dexmedetomidine ameliorates memory impairment in sleep-deprived mice. Anim Cells Syst (Seoul) 2019; 23: 371-9.
72. Tung A, Szafran MJ, Bhum B, Mendelson WB. Sleep deprivation potentiates the onset and duration of loss of righting reflex induced by propofol and isoflurane. Anesthesiology 2002; 97: 906-11.
73. Leung JM, Sands LP, Newman S, Meckler G, Xie Y, Gay C, et al. Preoperative sleep disruption and postoperative delirium. J Clin Sleep Med 2015; 11: 907-13.

74. Eikermann M, Vetrivelan R, Grosse-Sundrup M, Henry ME, Hoffmann U, Yokota S, et al. The ventrolateral preoptic nucleus is not required for isoflurane general anesthesia. Brain Res 2011; 1426: 30-7.

75. Eikermann M, Akeju O, Chamberlin NL. Sleep and anesthesia: the shared circuit hypothesis has been put to bed. Curr Biol 2020; 30: R219-21.